ARTICLE | Strategy
Amgen's new global view
February 11, 2008 8:00 AM UTC
Amgen Inc. says last week's three-part deal with Takeda Pharmaceutical Co. Ltd.. has little to do with its current restructuring. Instead, Amgen says the deal has more to do with sharing global development expenses.
Takeda received exclusive Japanese rights to 12 biologics being developed in Japan, agreed to acquire Amgen's Amgen K.K. Japanese subsidiary, and became the biotech's worldwide partner for motesanib (AMG 706), an oral agent that inhibits angiogenesis by targeting VEGF receptors 1, 2 and 3; platelet-derived growth factor (PDGF) receptor; and c-kit...